🇺🇸 FDA
Pipeline program

A study to compare the amount of milvexian in blood when given as pediatric and adult tablet formulations, to assess the effect of food intake on the absorption of pediatric milvexian tablet formulation in healthy adult participants and to assess the acceptability of different milvexian formulations.

Phase 1 other active

Quick answer

A study to compare the amount of milvexian in blood when given as pediatric and adult tablet formulations, to assess the effect of food intake on the absorption of pediatric milvexian tablet formulation in healthy adult participants and to assess the acceptability of different milvexian formulations. for atherothrombotic and thromboembolic disorders is a Phase 1 program (other) at Janssen-Cilag International N.V. with 1 ClinicalTrials.gov record(s).

Program details

Company
Janssen-Cilag International N.V.
Indication
atherothrombotic and thromboembolic disorders
Phase
Phase 1
Modality
other
Status
active

Clinical trials